186 related articles for article (PubMed ID: 31569370)
41. Changes in classification of genetic variants in BRCA1 and BRCA2.
Kast K; Wimberger P; Arnold N
Arch Gynecol Obstet; 2018 Feb; 297(2):279-280. PubMed ID: 29302806
[TBL] [Abstract][Full Text] [Related]
42. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.
Fierheller CT; Guitton-Sert L; Alenezi WM; Revil T; Oros KK; Gao Y; Bedard K; Arcand SL; Serruya C; Behl S; Meunier L; Fleury H; Fewings E; Subramanian DN; Nadaf J; Bruce JP; Bell R; Provencher D; Foulkes WD; El Haffaf Z; Mes-Masson AM; Majewski J; Pugh TJ; Tischkowitz M; James PA; Campbell IG; Greenwood CMT; Ragoussis J; Masson JY; Tonin PN
Genome Med; 2021 Dec; 13(1):186. PubMed ID: 34861889
[TBL] [Abstract][Full Text] [Related]
43. Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay.
Sirisena N; Biswas K; Sullivan T; Stauffer S; Cleveland L; Southon E; Dissanayake VHW; Sharan SK
Breast Cancer Res; 2020 May; 22(1):43. PubMed ID: 32393398
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
45. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Tram E; Savas S; Ozcelik H
PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
[TBL] [Abstract][Full Text] [Related]
46. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S
Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675
[TBL] [Abstract][Full Text] [Related]
47. GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes.
Caleca L; Colombo M; van Overeem Hansen T; Lázaro C; Manoukian S; Parsons MT; Spurdle AB; Radice P
Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30696104
[TBL] [Abstract][Full Text] [Related]
48. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI; Rodrigues M; Sandoval JL; Kurtz JE; Heitz F; Mosconi AM; Romero I; Denison U; Nagao S; Vergote I; Parma G; Nøttrup TJ; Rouleau E; Garnier G; El-Balat A; Zamagni C; Martín-Lorente C; Pujade-Lauraine E; Fiévet A; Ray-Coquard IL
Ann Oncol; 2023 Feb; 34(2):152-162. PubMed ID: 36564284
[TBL] [Abstract][Full Text] [Related]
49. Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide.
San Filippo J; Chi P; Sehorn MG; Etchin J; Krejci L; Sung P
J Biol Chem; 2006 Apr; 281(17):11649-57. PubMed ID: 16513631
[TBL] [Abstract][Full Text] [Related]
50. Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
Fraile-Bethencourt E; Díez-Gómez B; Velásquez-Zapata V; Acedo A; Sanz DJ; Velasco EA
PLoS Genet; 2017 Mar; 13(3):e1006691. PubMed ID: 28339459
[TBL] [Abstract][Full Text] [Related]
51. Clinically Significant Unclassified Variants in
Yoon KA; Park B; Lee BI; Yang MJ; Kong SY; Lee ES
Cancer Res Treat; 2017 Jul; 49(3):627-634. PubMed ID: 27658390
[TBL] [Abstract][Full Text] [Related]
52. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
De Nicolo A; Parisini E; Zhong Q; Dalla Palma M; Stoeckert KA; Domchek SM; Nathanson KL; Caligo MA; Vidal M; Cusick ME; Garber JE
Cancer Res; 2009 Sep; 69(17):7030-7. PubMed ID: 19706752
[TBL] [Abstract][Full Text] [Related]
53. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
54. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
[No Abstract] [Full Text] [Related]
55. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Chenevix-Trench G; Healey S; Lakhani S; Waring P; Cummings M; Brinkworth R; Deffenbaugh AM; Burbidge LA; Pruss D; Judkins T; Scholl T; Bekessy A; Marsh A; Lovelock P; Wong M; Tesoriero A; Renard H; Southey M; Hopper JL; Yannoukakos K; Brown M; Easton D; Tavtigian SV; Goldgar D; Spurdle AB;
Cancer Res; 2006 Feb; 66(4):2019-27. PubMed ID: 16489001
[TBL] [Abstract][Full Text] [Related]
56. Molecular characterization, homology modeling and docking studies of the R2787H missense variation in BRCA2 gene: Association with breast cancer.
Riahi A; Messaoudi A; Mrad R; Fourati A; Chabouni-Bouhamed H; Kharrat M
J Theor Biol; 2016 Aug; 403():188-196. PubMed ID: 27211102
[TBL] [Abstract][Full Text] [Related]
57. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Spearman AD; Sweet K; Zhou XP; McLennan J; Couch FJ; Toland AE
J Clin Oncol; 2008 Nov; 26(33):5393-400. PubMed ID: 18824701
[TBL] [Abstract][Full Text] [Related]
58. Cosmic Whirl: Navigating the Comet Trail in DNA: H2AX Phosphorylation and the Enigma of Uncertain Significance Variants.
Ustun Yilmaz S; Agaoglu NB; Manto K; Muftuoglu M; Özbek U
Genes (Basel); 2024 Jun; 15(6):. PubMed ID: 38927659
[TBL] [Abstract][Full Text] [Related]
59. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
[TBL] [Abstract][Full Text] [Related]
60. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
